## Letter to the Editor

Published in POLITICO, November 9, 2011

While I supported the Federal Trade Commission's challenge of anticompetitive, "pay-for-delay" settlements between brand-name and generic drugmakers in the past, I oppose Chairman Jon Leibowitz's opinion piece, "To Out Deficit, Out Sweetheart Drug Deals" (POLITICO, Nov. 1).

First, the proposed legislation does not treat all these settlements as "sweetheart deals," or even